PreveCeutical Medical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PREV.CN research report →
Companywww.preveceutical.com
PreveCeutical Medical Inc. , a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity.
- CEO
- Stephen Van Deventer
- IPO
- 2017
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $11.74M
- P/E
- -7.37
- P/S
- 0.00
- P/B
- -1.92
- EV/EBITDA
- -4.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 23.09%
- ROIC
- 339.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,584,312 · -134849.91%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-3,367,111
- FCF YoY
- -302.07%
Performance & Tape
- 52W High
- $0.06
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.07
- Avg Volume
- 100.80K
Get TickerSpark's AI analysis on PREV.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PREV.CN Coverage
We haven't published any research on PREV.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PREV.CN Report →